Regencell Bioscience (NASDAQ:RGC) Stock Price Down 8.9% – What’s Next?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s share price traded down 8.9% on Tuesday . The stock traded as low as $27.13 and last traded at $28.10. 69,823 shares were traded during mid-day trading, a decline of 83% from the average session volume of 409,729 shares. The stock had previously closed at $30.83.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Regencell Bioscience Stock Performance

The stock’s 50-day moving average price is $27.12 and its 200 day moving average price is $22.05.

Hedge Funds Weigh In On Regencell Bioscience

Institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC bought a new position in shares of Regencell Bioscience during the second quarter valued at approximately $1,701,000. BNP Paribas Financial Markets bought a new position in shares of Regencell Bioscience during the second quarter valued at approximately $768,000. XTX Topco Ltd bought a new position in shares of Regencell Bioscience during the third quarter valued at approximately $598,000. Hudson Bay Capital Management LP bought a new position in shares of Regencell Bioscience during the fourth quarter valued at approximately $275,000. Finally, Vident Advisory LLC boosted its stake in shares of Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after purchasing an additional 11,866 shares in the last quarter. 0.13% of the stock is owned by hedge funds and other institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.